Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490376 | ||
| 003 | CHVBK | ||
| 005 | 20210128100504.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0694-2 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0694-2 | ||
| 245 | 0 | 0 | |a Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series |h [Elektronische Daten] |c [Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, Franco Nolè, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri, Aron Goldhirsch] |
| 520 | 3 | |a Background: Estramustine phosphate sodium (EMP) is an oral agent poorly developed—although active—in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective series of consecutive patients with estrogen receptor-positive disease. Methods: EMP was given orally at a dose of 140mg daily. Treatment discontinuation rates due to progressive disease/toxicity and response rates were assessed. Results: Twenty postmenopausal patients with mainly visceral disease were treated with EMP, in five cases in combination with other anticancer drugs. Median numbers of previous chemotherapies and hormonal treatments were six and four, respectively. From the entire cohort, one complete response and four partial responses were observed. The proportions of patients free of progression at 6 and 12months were 39 and 8%, respectively. Six patients discontinued EMP, three each for toxicity and adverse events. Conclusion: Good disease control was obtained in heavily pretreated MBC patients receiving EMP. Toxicity was manageable and reversible although treatment discontinuation has to be considered. A prospective study should be encouraged to identify the optimal use of the drug. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Estramustine phosphate sodium |2 nationallicence | |
| 690 | 7 | |a Metastatic |2 nationallicence | |
| 690 | 7 | |a Breast cancer |2 nationallicence | |
| 700 | 1 | |a Aurilio |D Gaetano |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | |
| 700 | 1 | |a Graffeo |D Rossella |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | |
| 700 | 1 | |a Bagnardi |D Vincenzo |u Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, Milan, Italy |4 aut | |
| 700 | 1 | |a Nolè |D Franco |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | |
| 700 | 1 | |a Adamoli |D Laura |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | |
| 700 | 1 | |a Pagani |D Olivia |u Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale Italiano, Via Capelli, 6962, Viganello, Lugano, Switzerland |4 aut | |
| 700 | 1 | |a Gallerani |D Elisa |u Multimedica Castellanza, Viale Piemonte 70, 21053, Castellanza, Varese, Italy |4 aut | |
| 700 | 1 | |a Ferrari |D Benvenuto |u Multimedica Castellanza, Viale Piemonte 70, 21053, Castellanza, Varese, Italy |4 aut | |
| 700 | 1 | |a Pruneri |D Giancarlo |u Department of Pathology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy |4 aut | |
| 700 | 1 | |a Goldhirsch |D Aron |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 90-94 |x 1341-9625 |q 20:1<90 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0694-2 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0694-2 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Aurilio |D Gaetano |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Graffeo |D Rossella |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Bagnardi |D Vincenzo |u Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, Milan, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nolè |D Franco |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Adamoli |D Laura |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Pagani |D Olivia |u Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale Italiano, Via Capelli, 6962, Viganello, Lugano, Switzerland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Gallerani |D Elisa |u Multimedica Castellanza, Viale Piemonte 70, 21053, Castellanza, Varese, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ferrari |D Benvenuto |u Multimedica Castellanza, Viale Piemonte 70, 21053, Castellanza, Varese, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Pruneri |D Giancarlo |u Department of Pathology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Goldhirsch |D Aron |u Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 90-94 |x 1341-9625 |q 20:1<90 |1 2015 |2 20 |o 10147 | ||